Two recent developments of opioid peptide-based analgesics are reviewed. The fi rst part of the review discusses the dermorphin-derived, cationic-aromatic tetrapeptide H-Dmt-D-Arg-Phe-Lys-NH 2 ([Dmt 1 ]DALDA, where Dmt indicates 2 ′ ,6 ′ -dimethyltyrosine), which showed subnanomolar m receptor binding affi nity, extraordinary m receptor selectivity, and high m agonist potency in vitro. In vivo, [Dmt 1 ]DALDA looked promising as a spinal analgesic because of its extraordinary antinociceptive effect (3000 times more potent than morphine) in the mouse tail-fl ick assay, long duration of action (4 times longer than morphine), and lack of effect on respiration. Unexpectedly, [Dmt 1 ]DALDA also turned out to be a potent and long-acting analgesic in the tail-fl ick test when given subcutaneously (s.c.), indicating that it is capable of crossing the blood-brain barrier. Furthermore, little or no cross-tolerance was observed with s.c. [Dmt 1 ]DALDA in morphine-tolerant mice. The second part of the review concerns the development of mixed µ agonist/ d antagonists that, on the basis of much evidence, are expected to be analgesics with a low propensity to produce tolerance and physical dependence. The prototype pseudopeptide H-Dmt-Tic Y [CH 2 NH]PhePhe-NH 2 (DIPP-NH 2 [ Y ], where Tic indicates 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) showed subnanomolar m and d receptor binding affi nities and the desired m agonist/ d antagonist profi le in vitro. [ Y ] produced a potent analgesic effect after intracerebroventricular administration in the rat tail-fl ick assay, no physical dependence, and less tolerance than morphine. The results obtained with DIPP-NH 2 [ Y ] indicate that mixed m agonist/ d antagonists look promising as analgesic drug candidates, but compounds with this profi le that are systemically active still need to be developed.
INTRODUCTION
The clinical treatment of severe pain relies heavily upon opioid analgesics, most of which act via m opioid receptors.
Morphine and other centrally acting m opioid analgesics produce, in addition to the analgesic effect, several side effects -including inhibition of gastrointestinal motility, respiratory depression, tolerance, and physical dependence -that limit their use in pain treatment. Kappa opioid agonists have also been shown to be potent analgesics; however, it has long been recognized that centrally acting k agonists have limited usefulness in humans because of their psychotomimetic and dysphoric effects. 1 , 2 Delta opioid agonists are known to produce analgesic effects when given intrathecally (i.th) 3 , 4 or intracerebroventricularly (i.c.v.). 4 There is evidence to indicate that they induce less tolerance and physical dependence than m analgesics, no respiratory depression, and few or no adverse gastrointestinal effects. [5] [6] [7] Among the peptide d opioid agonists, [D-Pen 2 , D-Pen 5 ]enkephalin (DPDPE) produced only a weak, centrally mediated analgesic effect after systemic administration, indicating that it does not cross the blood-brain barrier (BBB) to a signifi cant extent. 8 Interestingly, the d -selective and highly stable cyclic lanthionine enkephalin analog H-Tyr-c[D-Val L -Gly-Phe-D-Ala L ]-OH was as active as morphine in producing centrally mediated analgesia when given intraperitoneally. 9 Several nonpeptide compounds showing potent and selective d agonist activity in vitro were developed. These include TAN-67, 10 the racemic compound BW373U86, 11 and its chemically modifi ed enantiomer SNC80. 12 These compounds produced analgesic effects when administered i.th. or i.c.v. but showed very low or no analgesic activity when given systemically. Furthermore, both BW373U86 and SNC80 produced convulsions in mice. Numerous compounds structurally derived from SNC80 were synthesized, and some were shown to be potent and selective d agonists in in vitro assays. 13 However, analgesic data for these compounds have not yet been published. It remains to be seen whether d opioid agonists that are effi cacious enough to produce strong centrally mediated analgesic effects when given systemically or orally can indeed be developed.
Progress has been made in the development of peripherally acting k and m opioid agonists (for a review, see DeHavenHudkins and Dolle). 14 Since such compounds have no or very low ability to cross the BBB, they are expected not to produce the typical side effects mediated by central k and m opioid receptors ( vide supra ). There is evidence to indicate E561 that peripherally restricted opioid analgesics produce antinociceptive effects under infl ammatory conditions through local interaction with opioid receptors present on peripheral nerve terminals. Peripherally acting k and m opioid agonists may be effective as analgesics in various infl ammatory pain states, for the treatment of visceral and postoperative pain, and as antipruritic agents. Most of the peripherally restricted opioids developed so far are still in the preclinical phase, and their promise as therapeutic agents needs to be confi rmed in clinical trials.
In this paper, we review 2 recent developments of opioid peptide-based analgesics with novel activity profi les or with distinct physicochemical properties. The fi rst part discusses the pharmacological characteristics of the m opioid agonist tetrapeptide H-Dmt-D-Arg-Phe-Lys-NH 2 ([Dmt 1 ]DALDA, where Dmt indicates 2 ′ ,6 ′ -dimethyltyrosine), which has therapeutic potential for use in spinal analgesia and is capable of crossing the BBB. The second part discusses the development of opioid peptides that act as agonists at the m opioid receptor and as antagonists at the d receptor. Opioid compounds with such a mixed m agonist/ d antagonist profi le look promising as analgesics with a low propensity to produce tolerance and dependence.
[DMT 1 ]DALDA
The dermorphin-derived tetrapeptide H-Tyr-D-Arg-PheLys-NH 2 (DALDA) 15 carries a net positive charge of 3+. In vitro it displayed m agonist activity in the guinea pig ileum (GPI) assay, low nanomolar m receptor binding affi nity, and extraordinary m receptor selectivity ( Table 1 ) . Replacement of the Tyr 1 residue in this peptide with 2 ′ ,6 ′ -dimethyltyrosine (Dmt) led to a compound, [Dmt 1 ]DALDA, which showed 180-fold increased m agonist potency in the GPI assay, subnanomolar m receptor binding affi nity, and still excellent m receptor selectivity. 16 The high m receptor binding affi nity and excellent m selectivity of this peptide were confi rmed in another binding study that, furthermore, indicated some preference for m 1 receptors (K i = 0.05 ± 0.02 nM) over m 2 receptors (K i = 0.27 ± 0.13 nM). 17 As expected on the basis of its structural characteristics, [Dmt 1 ]DALDA was found to be highly stable against enzymatic degradation when incubated in sheep blood. 19 When given i.th. to rats, [Dmt 1 ]DALDA was extremely active in producing an analgesic effect in the tail-fl ick assay: it was 3000 times more potent than morphine. 20 The same extraordinary antinociceptive potency of i.th. [Dmt 1 ]DALDA was also observed in the mouse tail-fl ick assay. 19 The observation that [Dmt 1 ]DALDA had only 7-fold higher m receptor binding affi nity than morphine ( Table 1 ) suggested that this peptide may produce its extraordinarily potent antinociceptive effect via additional mechanisms. Interestingly, it was found that [Dmt 1 ]DALDA inhibited norepinephrine uptake in rat spinal cord synaptosomes with an IC 50 of 4.1 m M. 20 Thus, i.th. administration of [Dmt 1 ]DALDA results in activation of both m opioid receptors and a 2 -adrenergic receptors in a synergistic manner known to potentiate the antinociceptive effect of m opioid agonists. 21 This interpretation is in tune with the observation that the antinociceptive response to [Dmt 1 ]DALDA was attenuated by i.th. yohimbine, an a 2 -adrenergic antagonist. 20 Furthermore, it 31 A study using different strains of mice demonstrated that the intensity of the withdrawal syndrome after chronic morphine treatment correlated with the level of d binding sites. 32 Furthermore, the development of morphine tolerance and dependence following chronic morphine administration was blocked by an antisense oligodeoxynucleotide to the d opioid receptor. 33 Finally, morphine was shown to retain its m receptor mediated analgesic activity in d opioid receptor knockout mice without producing tolerance upon chronic administration. 34 Very recently, d receptor antagonists were shown to enhance morphine-mediated i.th. analgesia, possibly as a consequence of m -d receptor heterodimerization. 35 These various observations clearly indicate that d opioid receptors play a major role in the development of morphine tolerance and dependence and provide a rationale for the development of an opioid compound acting as an agonist at the m receptor and as an antagonist at the d receptor. Such a mixed m agonist/ d antagonist would be expected to be an analgesic with low propensity to produce analgesic tolerance and physical dependence, and might be of benefi t in the management of chronic pain. Furthermore, it has been shown that the d antagonist naltrindole reversed alfentanil (a m agonist) induced respiratory depression 36 and enhanced colonic propulsion. 37 These results suggest that a mixed m agonist/ d antagonist might also cause less respiratory depression and less inhibition of gastrointestinal transit than a m agonist like morphine.
The fi rst known compound with a mixed m agonist/ d antagonist profi le was the tetrapeptide amide H-Tyr-Tic-Phe-Phe-NH 2 (TIPP-NH 2 ). 38 0.11 m g ). 39 At high doses (i.c.v.) it produced less acute analgesic tolerance than morphine but still a certain level of chronic tolerance. Unlike morphine, DIPP-NH 2 [ Y ] produced no physical dependence upon chronic i.c.v. infusion at high dose levels (up to 4.5 m g/h) over a 7-day period. 39 is due to some interference between the 2 components caused specifi cally by their " tail-to-tail " coupling. This chimeric peptide is currently being examined for its ability to produce a centrally mediated antinociceptive effect after administration by various routes.
Pyridomorphinans with a partial m agonist/ d antagonist profi le in vitro have been reported to produce a partial or full agonist effect in the warm-water tail-withdrawal assay after i.c.v. administration and a reduced level of tolerance. 42 , 43 The best compound of this class was 10-fold less potent than morphine. Taken together, the results obtained with DIPP-NH 2 [ Y ] and with the pyridomorphinans indicate that mixed m agonist/ d antagonists look promising as analgesic drug candidates; however, compounds with this profi le that have higher m agonist potency and higher effi cacy and that are systemically active still need to be developed.
